39,202 CVS Health Corporation $CVS Shares Acquired by Triasima Portfolio Management inc.

Key Points

• Triasima Portfolio Management increased its CVS Health stake by 119.8% in the third quarter, acquiring 39,202 additional shares for a total holding valued at approximately $6.16 million. Institutional investors collectively own 80.66% of the company.
• Analysts maintain a broadly positive outlook, with 20 Buy ratings and three Holds producing a consensus “Moderate Buy” rating and an average price target of $107.80.
• CVS reported stronger-than-expected quarterly results, with EPS of $2.58 versus the $1.87 consensus and revenue of $106.10 billion. The company also declared a quarterly dividend of $0.665 per share, representing a 2.9% annualized yield.

Triasima Portfolio Management inc. lifted its position in CVS Health Corporation (NYSE:CVS - Free Report) by 119.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,917 shares of the pharmacy operator's stock after acquiring an additional 39,202 shares during the quarter. Triasima Portfolio Management inc.'s holdings in CVS Health were worth $6,163,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Kilter Group LLC bought a new stake in CVS Health in the second quarter worth about $27,000. Sankala Group LLC purchased a new position in shares of CVS Health during the fourth quarter valued at approximately $28,000. Global Trust Asset Management LLC grew its stake in shares of CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 300 shares during the last quarter. J.Safra Asset Management Corp bought a new position in shares of CVS Health during the second quarter valued at approximately $30,000. Finally, Beaird Harris Wealth Management LLC grew its stake in shares of CVS Health by 201.0% during the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator's stock valued at $30,000 after buying an additional 195 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CVS. Sanford C. Bernstein reissued an "outperform" rating and set a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Cantor Fitzgerald restated a "neutral" rating on shares of CVS Health in a report on Friday, October 9th. Wells Fargo & Company upped their price objective on CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Leerink Partners reduced their target price on CVS Health from $119.00 to $112.00 and set an "outperform" rating on the stock in a research note on Monday. Finally, HSBC reiterated a "hold" rating and set a $103.00 target price on shares of CVS Health in a research report on Monday, July 6th. Twenty research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $107.80.

CVS Health Stock Performance

CVS stock opened at $92.45 on Friday. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68. The business has a 50-day moving average price of $91.80 and a 200 day moving average price of $93.03. The company has a market capitalization of $118.25 billion, a P/E ratio of 24.46, a PEG ratio of 0.84 and a beta of 0.60. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. The company had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm's quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities research analysts forecast that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be paid a dividend of $0.6650 per share. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health's dividend payout ratio (DPR) is currently 70.37%.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Improving fundamentals and valuation support the stock. CVS has recently exceeded earnings and revenue expectations, while analysts cited stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare. Its Aetna turnaround is also viewed as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: Expanded care access and quality credentials reinforce CVS’s healthcare-services strategy. CVS opened its first pharmacy-focused location in the Boston area to improve access to medications, immunizations and other services. Separately, MinuteClinic received its seventh consecutive Joint Commission accreditation, with primary care available at more than 65% of its locations. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: New women’s-health collaboration could support longer-term engagement. CVS is partnering with The Midlife Collective on a research study and documentary focused on women’s midlife health. The initiative may strengthen brand awareness and consumer relationships, but it is unlikely to have a near-term financial impact. CVS Health Collaborates With The Midlife Collective
• Positive Sentiment: Home-based heart monitoring expands value-added services. Signify Health, part of CVS, offers continuous heart-rhythm monitoring for eligible health-plan members, potentially enabling earlier detection of serious conditions and supporting preventive-care economics. CVS Health: Early Detection Matters
• Negative Sentiment: $315 million opioid settlement creates legal, financial and reputational pressure. CVS agreed to settle Justice Department allegations involving unlawful opioid dispensing and false claims. The company admitted no wrongdoing but will implement tighter controlled-substance oversight, adding costs and highlighting compliance risks. CVS Agrees to Pay $315M

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company's major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.